Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, single center, randomized, placebo-controlled, double-blind, multiple
ascending dose study to evaluate the safety and tolerability of CRS3123, a methionyl-tRNA
synthetase inhibitor. In this study, doses of 200, 400, and 600 mg, or 100mg are planned and
will be given orally every 12 hours for 10 days. Up to 30 healthy male and female subjects 18
to 45 years, inclusive. The primary objective: of the study is to determine the safety and
tolerability of escalating doses of CRS3123 following oral administration of multiple doses
to healthy adults. The study duration is 46 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)